Skip to content

Mechanical Treatment Peri-Implant Mucositis

Mechanical Treatment of Peri-Implant Mucositis -the Effect of Submucosal Instrumentation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05664425
Acronym
MechTreatPiM
Enrollment
56
Registered
2022-12-23
Start date
2023-03-01
Completion date
2025-02-25
Last updated
2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implant Mucositis

Brief summary

This two-arm, single-blinded, monocentric, controlled, randomised clinical study is designed to examine the effect of professional submucosal treatment by means of ultrasonics with plastic tip (test group), as compared to no professional submucosal instrumentation (control group), in the treatment of peri-implant mucositis (PIM). Both groups will have oral hygiene instruction/reinforcement (OHI) at baseline and repeated at 3 months. In the study, 50 participants will be enrolled (25 per group), with each patient contributing one implant with PIM. Peri-implant sulcus fluid (PISF) samples will be obtained at baseline, 3- and 6-months to analyse the change of relevant biomarkers over the course of PIM treatment. Intraoral scans will be performed at baseline, 3- and 6-months to analyse potential soft-tissue volumetric changes according to treatment.

Interventions

Ultrasonic debridement with a plastic/teflon tip (2 minutes + 1 minute irrigation)

Sponsors

University of Oslo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Masking description

Investigator-blinded

Intervention model description

Parallell group two-arm randomised study

Eligibility

Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject must be ≥ 20 years * Subject must have one implant presenting PIM as defined according to the World Workshop 2017 criteria (presence of BoP and/or suppuration (SoP), without bone loss exceeding 0.5 mm beyond crestal bone level changes resulting from initial remodeling, regardless of PPD. In absence of baseline radiographs (i.e., 0-1 year after loading) a bone level of \<2mm from the top of the intraosseous part of the implant is considered as the reference threshold) * Cleansable prosthesis (an interproximal brush must be able to pass from side to side at interproximal aspects tangential to the peri-implant sulcus, and a brush has to be able to reach the buccal and palatal/lingual sulcus). * No evidence of occlusal overload * No cement remnants identified on radiographs or clinically * Implant-supported fixed restoration inserted at least 6 months before patient enrolment and not interfering with assessment of clinical parameters at more than 3/6 sites * Periodontally healthy subjects or treated periodontitis (no residual site with PPD ≥ 5 mm) * Full-mouth plaque (FMPS) and bleeding (FMBS) score ≤ 20%¬¬¬¬¬¬¬ at screening visit * Non-smokers or light-smokers (\<10 cigarettes per day) * Competent to give consent

Exclusion criteria

* Previous radiotherapy, current use of chemotherapy, systemic long-term corticosteroid treatment * Hematologic disorders * Pregnant subjects * Patients classified as \> class 2 according to the ASA (American Society of Anesthesiologists) physical status classification * No systemic antibiotic treatment within 3 months prior to intervention

Design outcomes

Primary

MeasureTime frameDescription
Bleeding on probing (BoP) extent6 monthsReduction in the extent of BoP as measured on six sites per implant

Secondary

MeasureTime frameDescription
Intraoral digital scan6 monthsVolumetric change of soft tissue following peri-implant mucositis treatment
Disease resolution6 monthsNo BoP at any of the six probed sites at 6-month follow-up
Severity of BoP6 monthsReduction in the severity of BoP (graded from 0-3) at 6 months
Peri-implant sulcus fluid (PISF) biomarkers6 monthsBiomarkers sampled at baseline, 3- and 6-months
Bone level changes6 monthsChanges in bone level as assessed by radiographs at baseline and 6-months
Onset of peri-implantitis6 monthsIf peri-implantitis is diagnosed during or following the study, this will be reported. Peri-implantitis is defined as progressive bone loss identified by an increase of PPD changes or bone level changes.
Probing pocket depth (PPD) reduction6 monthsReduction in PPD at 6 months

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026